Effect of chronic GH overproduction on cardiac ANP expression and circulating ANP levels.
Sodium and water retention are common in acromegaly and upon GH administration. The underlying mechanisms, however, have not been clearly characterized as yet. Therefore, the aim of this study was to examine possible alterations of atrial natriuretic peptide (ANP), an endogenous regulator of volume homeostasis, in response to chronic elevated GH. We used GH-transgenic mice (GH-TM) as a model for chronic hypersomatotropinemia and moreover investigated 7 and 27 week old animals, respectively, in order to discriminate between short and long term effects of GH overexpression. Hematocrit values were reduced in GH-TM compared to control animals and it is known that plasma volume is increased in these animals. Structural lesions of the kidney were found in the GH-TM, however, in the animals studied there were no signs of renal insufficiency as evidenced by serum creatinine and urea levels. The serum concentration of immunoreactive ANP (IR-ANP) determined by RIA was significantly (P < 0.005) elevated in the young GH-TM as compared to control littermates (81.7+/-13.3 vs. 50.9+/-10.8 fmol/ml). The increase in serum IR-ANP of 27 week old GH-TM, however did not reach the level of significance (57.13+/-16.3 vs. 50.25+/-16.4 fmol/ml). Serum samples of control mice as well as of the 7 week old animals mainly contained ANP 99-126, known to be the circulating form of ANP. In contrast, serum of 27 week old GH-TM predominantly showed the cardiac storage form of ANP, ANP 1-126. Cardiac expression of ANP was quantified by Northern blot analysis. mRNA coding for ANP was found 1.2- and 2-fold increased in the atria of 7 and 27 week old GH-TM, respectively. In parallel, a 2.2-fold (7 week) and 2-fold (27 week) increase of IR-ANP was observed in transgenic atria compared to tissue of control animals. In contrast, no significant difference of ANP mRNA expression or of content of IR-ANP was observed in the ventricles of both groups of animals. In conclusion, GH-TM show various alterations in their ANP status suggesting an influence of the peptide on the effect of GH in fluid retention.
Dirsch
V M
VM
Institute of Pharmacology, Toxicology and Pharmacy, University of Munich, Germany.
Wolf
E
E
Wanke
R
R
Schulz
R
R
Hermanns
W
W
Vollmar
A M
AM
D000375:Aging; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D015152:Blotting, Northern; D001835:Body Weight; D002851:Chromatography, High Pressure Liquid; D013006:Growth Hormone / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D006400:Hematocrit; D006984:Hypertrophy; D007668:Kidney / Q000378:metabolism / Q000473:pathology; D008099:Liver / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009206:Myocardium / Q000378:metabolism*; D009929:Organ Size; D010446:Peptide Fragments / Q000097:blood / Q000276:immunology / Q000378:metabolism; D010953:Plasma Volume; D011498:Protein Precursors / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D011863:Radioimmunoassay
D010446:Peptide Fragments; D011498:Protein Precursors; D009320:Atrial Natriuretic Factor; D013006:Growth Hormone